X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (20) 20
melanoma (18) 18
oncology (15) 15
humans (14) 14
female (12) 12
male (12) 12
melanoma - drug therapy (11) 11
metastasis (11) 11
aged (10) 10
middle aged (10) 10
mutation (10) 10
survival (10) 10
adult (9) 9
cancer (9) 9
vemurafenib (9) 9
aged, 80 and over (8) 8
analysis (8) 8
care and treatment (8) 8
dabrafenib (8) 8
immunotherapy (8) 8
metastases (8) 8
braf (7) 7
clinical trials (7) 7
melanoma - genetics (7) 7
patients (7) 7
abridged index medicus (6) 6
ipilimumab (6) 6
mek inhibition (6) 6
melanoma - pathology (6) 6
mutations (6) 6
antineoplastic agents - administration & dosage (5) 5
antineoplastic agents - adverse effects (5) 5
chemotherapy (5) 5
hematology, oncology and palliative medicine (5) 5
improved survival (5) 5
medicine, general & internal (5) 5
melanoma - mortality (5) 5
metastatic melanoma (5) 5
proto-oncogene proteins b-raf - genetics (5) 5
skin neoplasms - drug therapy (5) 5
skin neoplasms - pathology (5) 5
trametinib (5) 5
treatment outcome (5) 5
young adult (5) 5
adolescent (4) 4
cobimetinib (4) 4
disease-free survival (4) 4
double-blind method (4) 4
immune checkpoint (4) 4
melanoma - secondary (4) 4
open-label (4) 4
pembrolizumab (4) 4
safety (4) 4
studies (4) 4
survival analysis (4) 4
tumors (4) 4
antibodies, monoclonal - administration & dosage (3) 3
antibodies, monoclonal - adverse effects (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
complications and side effects (3) 3
creatine (3) 3
creatine kinase (3) 3
dacarbazine - administration & dosage (3) 3
double-blind (3) 3
drug administration schedule (3) 3
drug dosages (3) 3
follow-up studies (3) 3
kaplan-meier estimate (3) 3
medical colleges (3) 3
myalgia (3) 3
nausea (3) 3
neoplasm staging (3) 3
nivolumab (3) 3
pd-1 protein (3) 3
pharmacology (3) 3
skin neoplasms - genetics (3) 3
skin neoplasms - mortality (3) 3
survival rate (3) 3
therapy (3) 3
toxicity (3) 3
alanine (2) 2
alanine transaminase (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antineoplastic agents - pharmacokinetics (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antitumor activity (2) 2
arthralgia (2) 2
benzimidazoles - administration & dosage (2) 2
biomarkers (2) 2
biotechnology (2) 2
body weight (2) 2
braf inhibitors (2) 2
cancer therapies (2) 2
clinical medicine (2) 2
colitis (2) 2
colitis - chemically induced (2) 2
combination (2) 2
compassionate use (2) 2
compassionate use trials (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 444 - 451
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 435 - 445
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 436 - 444
Summary Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows improved response rates, progression-free survival... 
Hematology, Oncology and Palliative Medicine
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 733 - 740
Summary Background Patients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has... 
Hematology, Oncology and Palliative Medicine | CELL LUNG-CANCER | TRIAL | KINASE KINASE-1/2 INHIBITOR | MULTICENTER | ONCOLOGY | ORAL MEK INHIBITOR | IMPROVED SURVIVAL | INHIBITOR AZD6244 ARRY-142886 | OPEN-LABEL | MUTATIONS | VEMURAFENIB | Dacarbazine - adverse effects | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents, Alkylating - administration & dosage | Skin Neoplasms - enzymology | Benzimidazoles - administration & dosage | Time Factors | DNA Mutational Analysis | Brazil | Proto-Oncogene Proteins B-raf - metabolism | Dacarbazine - administration & dosage | Genetic Predisposition to Disease | Neoplasms, Unknown Primary - genetics | Europe | Logistic Models | Antineoplastic Agents, Alkylating - therapeutic use | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Mutation | Antineoplastic Agents, Alkylating - adverse effects | Melanoma - mortality | Dacarbazine - therapeutic use | United States | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Melanoma - enzymology | Neoplasms, Unknown Primary - enzymology | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | Neoplasms, Unknown Primary - drug therapy | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Neoplasms, Unknown Primary - mortality | Melanoma - secondary | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Aged | Neoplasms, Unknown Primary - pathology | Care and treatment | Chemotherapy | Gene mutations | Analysis | Melanoma | Metastasis | Cancer
Journal Article
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10105, pp. 1853 - 1862
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 05/2019, Volume 30, Issue 5, pp. 766 - 773
Background: Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results... 
paclitaxel | first line | pertuzumab | dual HER2 blockade | HER2-positive | metastatic breast cancer | WEEKLY PACLITAXEL | ONCOLOGY | NAB-PACLITAXEL | PROGRESSION-FREE SURVIVAL | DOCETAXEL
Journal Article
European Journal of Cancer, ISSN 0959-8049, 09/2019, Volume 119, pp. 97 - 106
Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for V600-mutant metastatic... 
Encorafenib | Vemurafenib | Safety | Binimetinib | Melanoma | TRAMETINIB | INHIBITOR-ASSOCIATED RETINOPATHY | OPEN-LABEL | BRAF | COMBINED DABRAFENIB | MEK INHIBITOR | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | Complications and side effects
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 26, pp. 2521 - 2532
Journal Article